Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS wild-type pancreatic ductal adenocarcinoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Fusion testing is still missed when DNA panels are used alone, so many actionable tumours go unrecognised.
Each driver is too rare for pancreatic-specific randomised trials; evidence is extrapolated from lung cancer and basket studies.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Resistance to fusion-targeted drugs follows lung cancer patterns and second-line options are thin.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Some KRAS wild-type cases are misclassified periampullary cancers, which confounds every series.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.
A milestone in how this cancer is treated.
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.